Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama
- PMID: 15494875
- DOI: 10.1177/000992280404300802
Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama
Abstract
Childhood idiopathic thrombocytopenic purpura (ITP) is a common disorder. However, single-institution, long-term, natural history data are limited. The objective of this paper is to review presenting features, response to therapy, and natural history of ITP treated at a single pediatric academic medical center. A retrospective chart review was made for all children (ages birth-18 years) diagnosed with ITP (ICD 287.3) and treated at the Childrens Hospital of Alabama/University of Alabama at Birmingham between 1993 and 2003. Four hundred nine patients were identified (49% male, 51% female; mean age: 5.85 years; range: 1 month-17 years). There was no seasonal variation of presentation. The mean platelet count was 19k (0-120k). Bone marrow aspiration (BMA) was performed in 72% but altered the diagnosis or therapy in no patient. Treatment consisted of corticosteroids in 256 (92% response), intravenous immunoglobulin (IVIG) in 125 (87% response), Win-Rho D in 58 (91% response), and no therapy in 71 (100% response). Response was defined as increase in platelet count to > 50k. There was no difference in response to any therapy. No patients died. One patient presented with a CNS hemorrhage at presentation, responded to therapy, and survived. Twenty-three of 409 patients (6%) experienced clinical bleeding requiring hospitalization or blood transfusion. Chronic ITP (persistence > 6 months) was noted in 99 patients (24%). Chronic patients presented at an older age (7.8 vs 5.2 years for acute only, p<0.001), and with higher platelet counts (27k vs 17k, p<0.001). The risk of chronic ITP was partially predicted by presenting platelet count > 50k and age > 10 years, or both; 50% of patients presenting with these features developed chronic ITP vs 24% overall rate. Splenectomy was curative in 30/31 (97%) patients. There was no postsplenectomy sepsis. Of 99 patients with chronic ITP, 25 responded to splenectomy, 37 resolved at a mean of 20.3 months after diagnosis (7-96 months), 36 had persistent mild thrombocytopenia (50k-125k), and 1 failed to respond to any treatment including splenectomy. Overall, 91% of cases resolved with therapy or observation. ITP is a common pediatric disease presenting at any age with low morbidity and mortality. Most cases can be managed by pediatricians without hematology referral. Several equally successful therapeutic options exist. Chronic cases present at an older age with higher platelet counts. Up to 50% of cases of chronic ITP will resolve with ongoing follow-up. The overall prognosis in childhood ITP is excellent.
Similar articles
-
Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity.Pediatr Neonatol. 2019 Aug;60(4):411-416. doi: 10.1016/j.pedneo.2018.10.002. Epub 2018 Nov 3. Pediatr Neonatol. 2019. PMID: 30470618
-
Idiopathic thrombocytopenic purpura diagnosed during the second decade of life.J Pediatr. 2002 Aug;141(2):253-8. doi: 10.1067/mpd.2002.125909. J Pediatr. 2002. PMID: 12183723
-
Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.Acta Haematol. 2006;115(1-2):46-52. doi: 10.1159/000089465. Acta Haematol. 2006. PMID: 16424649 Clinical Trial.
-
Treatment of immune thrombocytopenic purpura in children : current concepts.Paediatr Drugs. 2005;7(5):325-36. doi: 10.2165/00148581-200507050-00004. Paediatr Drugs. 2005. PMID: 16220997 Review.
-
First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.Eur J Haematol Suppl. 2008 Feb;(69):19-26. doi: 10.1111/j.1600-0609.2007.01000.x. Eur J Haematol Suppl. 2008. PMID: 18211569 Review.
Cited by
-
Initial Lymphocyte Count as Prognostic Indicator for Childhood Immune Thrombocytopenia.Indian J Hematol Blood Transfus. 2017 Mar;33(1):93-96. doi: 10.1007/s12288-016-0664-0. Epub 2016 Mar 8. Indian J Hematol Blood Transfus. 2017. PMID: 28194063 Free PMC article.
-
Predictors for spontaneous remission in childhood chronic immune thrombocytopenia.Ann Hematol. 2024 Dec;103(12):5181-5189. doi: 10.1007/s00277-024-06056-5. Epub 2024 Oct 27. Ann Hematol. 2024. PMID: 39463182
-
Clinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old.Iran J Ped Hematol Oncol. 2016;6(1):24-31. Epub 2016 Mar 15. Iran J Ped Hematol Oncol. 2016. PMID: 27222699 Free PMC article.
-
Identification and characterization of anti-platelet antibodies in idiopathic thrombocytopenic purpura patients.Iran J Public Health. 2012;41(2):53-62. Epub 2012 Feb 29. Iran J Public Health. 2012. PMID: 23113135 Free PMC article.
-
American Society of Hematology 2019 guidelines for immune thrombocytopenia.Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966. Blood Adv. 2019. PMID: 31794604 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous